Research Papers

25 of 3284 papers

CSV Excel
Quick filters: Open Data Open Code Pre-registered Funding Declared COI Declared Open Access Clear Filters
Management Strategies of Breast Cancer Patients with <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Germline Variants.
Edaily S; Abdel-Razeq H.
Onco Targets Ther (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Evaluating the Therapeutic Potential of Idecabtagene Vicleucel in the Treatment of Multiple Myeloma: Evidence to Date.
Mann H; Comenzo RL.
Onco Targets Ther (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Potassium Channels as a Target for Cancer Therapy: Current Perspectives.
Zúñiga L; Cayo A; González W; Vilos C; Zúñiga R.
Onco Targets Ther (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Association Mining Identifies MAL2 as a Novel Tumor Suppressor in Colorectal Cancer.
Wang K; Yang Y; Zheng S; Hu W.
Onco Targets Ther (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Targeting <i>KRAS</i> <sup>G12C</sup>-Mutated Advanced Colorectal Cancer: Research and Clinical Developments.
Ji J; Wang C; Fakih M.
Onco Targets Ther (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Long-Term Efficacy and Safety of Anlotinib as a Monotherapy and Combined Therapy for Advanced Sarcoma.
Yao W; Du X; Wang J; Wang X; Zhang P; Niu X.
Onco Targets Ther (Unknown)
Published: 2022
2/6 Transparent
EGFR Mutation Status and Subtypes Predicted by CT-Based 3D Radiomic Features in Lung Adenocarcinoma.
Chen Q; Li Y; Cheng Q; Van Valkenburgh J; Sun X; Zheng C; Zhang R; Yuan R.
Onco Targets Ther (Unknown)
Published: 2022
2/6 Transparent
Circular RNA circLRCH3 Inhibits Proliferation, Migration, and Invasion of Colorectal Cancer Cells Through miRNA-223/LPP…
Yang Y; Wang D; Tao K; Wang G.
Onco Targets Ther (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Protein Expression of Folate Receptor Alpha in Adenoid Cystic Carcinoma of the Head and Neck.
Schnoell J; Jank BJ; Kadletz-Wanke L; Stoiber S; Gurnhofer E; Schlederer M; Heiduschka G; Kenner L.
Onco Targets Ther (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Identification of 1,2,4-Oxadiazoles-Based Novel EGFR Inhibitors: Molecular Dynamics Simulation-Guided Identification an…
Unadkat V; Rohit S; Parikh P; Patel K; Sanna V; Singh S.
Onco Targets Ther (Unknown)
Published: 2022
2/6 Transparent
TROP2 as Patient-Tailoring but Not Prognostic Biomarker for Breast Cancer.
Liu X; Zhou T; Wang Y; Pei M; Wang G; Chu W; Wang Q; Du S; Wang H; Wang C.
Onco Targets Ther (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Glioblastoma: Pitfalls and Opportunities of Immunotherapeutic Combinations.
Niedbała M; Malarz K; Sharma G; Kramer-Marek G; Kaspera W.
Onco Targets Ther (Unknown)
Published: 2022
2/6 Transparent
Targeting <i>TP53</i>-Mutated Acute Myeloid Leukemia: Research and Clinical Developments.
Granowicz EM; Jonas BA.
Onco Targets Ther (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Migfilin: Cell Adhesion Effect and Comorbidities.
Duan B; Qin Z; Gu X; Li Y.
Onco Targets Ther (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
An Innovative Site-Specific Anti-HER2 Antibody-Drug Conjugate with High Homogeneity and Improved Therapeutic Index.
Hui X; Yuan C; Cao W; Ge W; Zhang D; Dan M; Zhao Q; Liu B; Yao B.
Onco Targets Ther (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
CDKN3 Overcomes Bladder Cancer Cisplatin Resistance via LDHA-Dependent Glycolysis Reprogramming.
Li M; Che N; Jin Y; Li J; Yang W.
Onco Targets Ther (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
The Research Progress of Bufalin in the Treatment of Hepatocellular Carcinoma.
Jiang HY; Zheng HM; Xia C; Li X; Wang G; Zhao T; Cui XN; Wang RY; Liu Y.
Onco Targets Ther (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Exploring the Role of Transglutaminase in Patients with Glioblastoma: Current Perspectives.
Katt WP; Aplin C; Cerione RA.
Onco Targets Ther (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Airway <i>Fusobacterium</i> is Associated with Poor Response to Immunotherapy in Lung Cancer.
Chu S; Cheng Z; Yin Z; Xu J; Wu F; Jin Y; Yang G.
Onco Targets Ther (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Targeted Therapy for Relapsed/Refractory Follicular Lymphoma: Focus on Clinical Utility of Tazemetostat.
Raychaudhuri R; Ujjani C.
Onco Targets Ther (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Treatment Patterns and Outcomes Among Elderly Glioblastoma Patients in Riyadh, Saudi Arabia.
Marie A; Maklad A; AlTwairgi A; Aly M; Elyamany A; AlShaqweer W; Senosy M; Balbaid A.
Onco Targets Ther (Unknown)
Published: 2022
2/6 Transparent
Pexidartinib in the Management of Advanced Tenosynovial Giant Cell Tumor: Focus on Patient Selection and Special Consid…
Vaynrub A; Healey JH; Tap W; Vaynrub M.
Onco Targets Ther (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Role of Reactivating Mutant p53 Protein in Suppressing Growth and Metastasis of Triple-Negative Breast Cancer.
Berke TP; Slight SH; Hyder SM.
Onco Targets Ther (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Alectinib Together with Intracranial Therapies Improved Survival Outcomes in Untreated ALK-Positive Patients with Non-S…
Yin Q; Li P; Wang P; Zhang Z; Liu Q; Sun Z; Li W; Ma L; Wang X.
Onco Targets Ther (Unknown)
Published: 2021
3/6 Transparent
Funding Declared
Targeted Treatment of Chronic Lymphocytic Leukemia: Clinical Utility of Acalabrutinib.
Vitale C; Gibbons JL; Ferrajoli A.
Onco Targets Ther (Unknown)
Published: 2021
1/6 Transparent